乳房派杰氏病合并浸润性乳腺癌患者的生存分析

发布时间：2018-06-08 10:11

本文选题：派杰氏病 + 人表皮生长因子受体　；参考：《中国癌症杂志》2017年08期

【摘要】：背景与目的:乳房派杰氏病(Paget’s disease)是一种很罕见的疾病。文献报道该病患者的生存情况与其下乳房内的病灶的恶性程度相关。该研究旨在探索合并浸润性乳腺癌的乳房派杰氏病的临床病理特征并分析患者的生存率。方法:2002—2007年,共54例在复旦大学附属肿瘤医院接受治疗的合并浸润性乳腺癌的乳房派杰氏病患者纳入该研究。由于乳腺派杰氏病大多数为人表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)阳性,研究者随机收集了同期72例HER-2阳性浸润性乳腺癌患者作为对照组,比较两组的生存差异。结果:25例(46.3%)研究组患者没有典型的乳头乳晕派杰氏病皮肤表现,35例(64.8%)研究组患者浸润性癌灶超过2 cm,26例(48.1%)研究组患者腋窝淋巴结有转移。与对照组的患者相比,派杰氏病患者的复发事件更多(5年无复发生存率:76.4%vs 48.5%,P0.01)。对照组复发事件多集中于术后3年内,而派杰氏患者复发风险在术后5年内持续存在。研究组的5年总生存率(61.0%)也低于对照组(80.6%,P=0.01)。结论:合并浸润性癌的乳房派杰氏病患者比HER-2阳性乳腺癌患者的预后差。
[Abstract]:Background & objective: Pagettasis disease of breast is a rare disease. It is reported that the survival of the patients is related to the malignancy of the lesions in the lower breast. The aim of this study was to investigate the clinicopathological features of breast Paget's disease with invasive breast cancer and to analyze the survival rate. Methods from 2002 to 2007, 54 patients with Paget's disease of breast with invasive breast cancer received treatment at the Cancer Hospital affiliated to Fudan University were included in the study. As the majority of human epidermal growth factor receptor (2(human epidermal growth factor receptor 2) HER-2) positive in Paget's disease, the researchers randomly collected 72 HER-2 positive invasive breast cancer patients as the control group, and compared the survival of the two groups. Results there were no typical skin manifestations of papillary areola Paget's disease in the study group (25 cases 46.3%). 35 cases of Paget's disease with papillary areola were found in the study group. There were 26 cases of invasive carcinoma more than 2 cm in the study group and 26 cases had metastasis of axillary lymph nodes in the study group. Compared with the control group, Paget's disease patients had more recurrent events (5-year recurrence free survival rate: 76.4 vs 48.5 / P0.01g / kg). The recurrence events in the control group were mainly within 3 years after operation, while the recurrence risk of Paget patients persisted within 5 years after operation. The 5-year overall survival rate in the study group was also lower than that in the control group. Conclusion: the prognosis of Paget's disease with invasive carcinoma is worse than that of HER-2 positive breast cancer.
【作者单位】：复旦大学附属肿瘤医院乳腺外科复旦大学上海医学院肿瘤学系;复旦大学附属肿瘤医院病理科复旦大学上海医学院肿瘤学系;
【分类号】：R737.9

【相似文献】